Professor Richard Price
Contact information
Podcast interview
Curing Plasmodium vivax malaria
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Research groups
Ethiopian Clinic
Vietnam Hospital
Richard Price
Professor of Tropical Medicine
Vivax malaria
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with in malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria
- define the morbidity and mortality of vivax malaria
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN). Between 2010-2020 he established co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
CURRENT PROJECTS:
- Clinical trials and implementation studies of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Individual patient data metanalyses of antimalarial efficacy studies
Timika, Papua, Indonesia
RSMM Hospital
Sumatra Site for IMPROV Study
Ex vivo Lab
Recent publications
-
Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency
Taylor WRJ. et al, (2023), PLOS Neglected Tropical Diseases, 17, e0011522 - e0011522
-
The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial
Thriemer K. et al, (2023), BMC Medical Research Methodology, 23
-
A model for malaria treatment evaluation in the presence of multiple species
Walker CR. et al, (2023), Epidemics, 44, 100687 - 100687
-
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
Commons RJ. et al, (2023), The Lancet Infectious Diseases
-
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
Rajasekhar M. et al, (2023), The Lancet Infectious Diseases
-
Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses.
Yilma D. et al, (2023), The American journal of tropical medicine and hygiene